尽管季度损失和全年预计损失,但生物科技内部人员购买了170,000多股股票,显示出信心。 Oncolytics Biotech insiders bought over 170,000 shares, showing confidence despite a quarterly loss and projected full-year loss.

2026年2月11日至12日,包括CEO Jared Ryan Kelly、Bernd Robert Searinger 董事和其他人在内的多个Oncolytics生物技术内幕人士以每股0.85至C1.18美元的价格购买了总共170,000多股股份,表明对该公司的信心。 On February 11-12, 2026, multiple Oncolytics Biotech insiders, including CEO Jared Ryan Kelly, director Bernd Robert Seizinger, and others, purchased a combined total of over 170,000 shares at prices between $0.85 and C$1.18 per share, signaling confidence in the company. 这些采购是在每股季度损失0.10美元之后进行的,这比估计少了0.10美元,并随着公司在第3阶段对转移性乳腺癌和胰腺癌进行试验时的免疫治疗,即Pelareorep进步。 The purchases followed a quarterly loss of $0.10 per share, which beat estimates, and come as the firm advances pelareorep, an immunotherapeutic in phase 3 trials for metastatic breast and pancreatic cancers. 该公司的市场上限为8 860万至15亿美元(视汇率而定),其52周的存货在3.3美元至2.08美元之间,分析家预测全年每股损失0.41美元。 The company, with a market cap of $88.6 million to $1.5 billion depending on the exchange, has a 52-week stock range of $0.33 to $2.08 and analysts project a full-year loss of $0.41 per share.